No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Grape King Bio Ltd. is a Taiwanese enterprise specializing in the production and distribution of a diverse array of health-focused items, encompassing pharmaceuticals, traditional remedies, nourishing beverages, and dietary supplements. Its market presence spans Taiwan, mainland China, and various international regions. The company engages with customers through multiple operational avenues, including multi-level marketing channels, conventional distribution networks, and a significant original design and equipment manufacturing (ODM/OEM) division. Among its extensive product range are various mushroom mycelium derivatives, notably ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor. Additionally, it formulates and supplies probiotics featuring strains like enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium, alongside a selection of enzyme products. Beyond its own brand, Grape King Bio offers comprehensive contract services, such as original equipment manufacturing (OEM), original design manufacturing (ODM), custom formulation development, dedicated research and development support, and the provision of raw materials. Established in 1969, the firm maintains its corporate headquarters in Taoyuan City, Taiwan.
www.grapeking.com.twNo one on the platform currently holds 1707.TW.
No tracked institution reports a position in 1707.TW as of their last filing.
No one on the platform has traded 1707.TW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 24.7% | 33.7% | 35.0% | — | — | — |
| Rev. Growth % | -8.1% | 2.3% | ||||
| Profit Margin % | 11.9% | 15.9% | 16.4% | |||
| Free Cash Flow Margin % | 16.9% | 18.6% | 18.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $10.5B | +2.2% | $7.37 | $7.37–$7.37 | — | 1 |
| 2027 | $11.4B | +8.9% | $9.00 | $9.00–$9.00 | — | 1 |
| 2028 | $13.2B | +15.3% | $10.90 | $10.90–$10.90 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $1.47 | $1.47 | +0.0% |
| 2026-05-11 | $1.36 | $1.18 | -13.2% |
| 2026-03-04 | $2.84 | $2.84 | +0.0% |
| 2025-11-12 | $2.12 | $2.00 | -5.7% |
| 2025-08-08 | $2.28 | $2.28 | +0.0% |
| 2025-05-09 | $1.90 | $1.40 | -26.3% |
| 2025-02-26 | $3.60 | $3.02 | -16.1% |
| 2024-11-11 | $2.43 | $2.80 | +15.2% |
| $78.60 |
| +0.00% |
| $19.5B |
| — |
| 4114.TWOSynmosa Biopharma Corporation | $29.60 | +0.85% | $16.0B | — |
| 4147.TWOTaiMed Biologics Inc. | $62.30 | +2.47% | $16.9B | — |
Source: Financial Modeling Prep · peers by sector/industry